SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Dishman Carbogen Amc - Quaterly Results

23 May 2023 Evaluate
The sales for the March 2023 quarter moved up 34.12% to Rs. 1131.30 millions as compared to Rs. 843.50 millions during the corresponding quarter last year.The Net Loss for the quarter ended March 2023 is Rs. -102.30 millions as compared to Net Profit of Rs. 48.30 millions of corresponding quarter ended March 2022Operating profit for the quarter ended March 2023 rose to 211.40 millions as compared to 145.20 millions of corresponding quarter ended March 2022.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202303 202203 % Var 202303 202203 % Var 202303 202203 % Var
Sales 1131.30 843.50 34.12 4025.50 3066.10 31.29 4025.50 3066.10 31.29
Other Income 147.90 114.30 29.40 521.60 603.90 -13.63 521.60 603.90 -13.63
PBIDT 211.40 145.20 45.59 599.20 999.00 -40.02 599.20 999.00 -40.02
Interest 170.30 100.30 69.79 579.20 372.30 55.57 579.20 372.30 55.57
PBDT 41.10 10.80 280.56 0.00 567.60 -100.00 0.00 567.60 -100.00
Depreciation 234.50 344.90 -32.01 962.00 1400.70 -31.32 962.00 1400.70 -31.32
PBT -193.40 -334.10 -42.11 -962.00 -833.10 15.47 -962.00 -833.10 15.47
TAX -91.10 -382.40 -76.18 -373.30 -528.40 -29.35 -373.30 -528.40 -29.35
Deferred Tax -91.10 -75.60 20.50 -373.30 -221.60 68.46 -373.30 -221.60 68.46
PAT -102.30 48.30 -311.80 -588.70 -304.70 93.21 -588.70 -304.70 93.21
Equity 313.60 313.60 0.00 313.60 313.60 0.00 313.60 313.60 0.00
PBIDTM(%) 18.69 17.21 8.55 14.89 32.58 -54.32 14.89 32.58 -54.32

Dishman Carbogen Amc Share Price

167.55 -1.05 (-0.62%)
20-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.00
Dr. Reddys Lab 1232.25
Cipla 1228.90
Zydus Lifesciences 936.35
Lupin 2328.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×